NCT05256810View on ClinicalTrials.gov

A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions
Gout
Interventions
DRUG

ALN-XDH

ALN-XDH administered by SC injection

DRUG

Placebo

Placebo administered by SC injection

Trial Locations (1)

Unknown

Clinical Trial Site, London

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY